Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Ewing sarcoma
What changed

What changed: Ewing sarcoma

Cancer page →

Every dated change on the records linked to Ewing sarcoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Approval1Trial result5Milestone8This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-08This recordEwing sarcoma
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 2

2022MilestoneEwing sarcoma
Euro Ewing 2012: VDC/IE superior to VIDE (Lancet)
A milestone in how this cancer is treated.
2022MilestoneIfosfamide
rEECur: high-dose ifosfamide best of four relapse regimens
A milestone in how this cancer is treated.

2020 · 1

2020Trial resultCABONE
CABONE reported
Cabozantinib met the activity thresholds in both the Ewing sarcoma and osteosarcoma cohorts.

2019 · 1

2019Trial resultREGOBONE
REGOBONE reported
Regorafenib improved eight-week progression-free survival over placebo in relapsed osteosarcoma, with signals in the Ewing sarcoma and chondrosarcoma cohorts.

2018 · 1

2018MilestoneAutologous stem cell transplant (high-dose therapy)
Euro-EWING 99 R2: busulfan-melphalan benefit in high-risk localised disease
A milestone in how this cancer is treated.

2017 · 1

2017Trial resultSARC028
SARC028 reported
Pembrolizumab produced objective responses mainly in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, with little activity in bone sarcomas.

2016 · 1

2016Trial resultChildhood Cancer Survivor Study (CCSS)
Childhood Cancer Survivor Study (CCSS) reported
15-year all-cause mortality among five-year survivors fell from 12.

2012 · 2

2012Trial resultAEWS0031
AEWS0031 reported
Five-year event-free survival 73 percent with two-weekly (interval-compressed) chemotherapy against 65 percent with three-weekly chemotherapy (p 0.
2012MilestoneEwing sarcoma
AEWS0031: interval compression improves EFS (Womer, JCO)
A milestone in how this cancer is treated.

2003 · 1

2003MilestoneIfosfamide
INT-0091: adding ifosfamide-etoposide improves survival (Grier, NEJM)
A milestone in how this cancer is treated.

1992 · 1

1992MilestoneEwing sarcoma
EWSR1-FLI1 fusion cloned (Delattre, Nature)
A milestone in how this cancer is treated.

1974 · 1

1974MilestoneVincristine
IESS-I: adjuvant VAC + doxorubicin raises survival from ~10% to ~60%
A milestone in how this cancer is treated.

1964 · 1

1964ApprovalDactinomycin (actinomycin D)
Dactinomycin (actinomycin D) approved in US
Wilms tumour, rhabdomyosarcoma, Ewing sarcoma, gestational trophoblastic neoplasia, metastatic testicular cancer, regional perfusion for sarcoma

1921 · 1

1921MilestoneEwing sarcoma
James Ewing describes 'diffuse endothelioma of bone'
A milestone in how this cancer is treated.